Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paclitaxel Micelles for Injection is a nanoparticle formulation of the taxane chemotherapy agent paclitaxel, designed to improve the drug's solubility and safety profile. Unlike traditional paclitaxel formulations that require solvents like Cremophor EL (which can cause severe hypersensitivity reactions), this micellar formulation encapsulates paclitaxel within polymeric micelles. This delivery system aims to enhance the therapeutic index by increasing drug concentration at the tumor site through the enhanced permeability and retention (EPR) effect while reducing systemic toxicity. It is being evaluated in clinical trials sponsored by the First Affiliated Hospital of Zhejiang University for the treatment of various advanced solid tumors, including breast, ovarian, gastric, and non-small cell lung cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Paclitaxel Micelles for Injection.